GlassScriptPhysician profile
Brian C Douglas
NPI 1578540761
$6,880.69
in general payments reported to CMS, 2019-2025
27 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $1,042 · 2021: $1,094 · 2022: $1,198 · 2023: $1,067 · 2024: $997 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.78 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,021.30 | 2019-2023 | Rebyota, Clenpiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $961.31 | 2019-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $811.74 | 2019-2025 | Eohilia, Gattex, Entyvio |
| Celgene Corporation | $599.39 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $499.85 | 2019-2024 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $402.63 | 2021-2024 | Dificid, Zinplava |
| Romark Laboratories, Lc | $325.96 | 2019-2020 | |
| Exact Sciences Corporation | $311.94 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $302.09 | 2019-2024 | Linzess, Viberzi, Creon |
| Allergan, INC. | $242.61 | 2019-2020 | |
| Janssen Biotech, INC. | $233.22 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Redhill Biopharma INC. | $181.66 | 2020-2021 | |
| Intuitive Surgical, INC. | $152.12 | 2019 | |
| Madrigal Pharmaceuticals | $134.33 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $121.82 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $108.42 | 2021-2022 | |
| Alfasigma USA, INC. | $91.09 | 2020 | |
| Gilead Sciences, INC. | $55.82 | 2022 | |
| Ironwood Pharmaceuticals, INC | $41.06 | 2022 | |
| Concordia Pharmaceuticals INC. | $32.60 | 2019 | |
| Celltrion USA INC. | $29.84 | 2024 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $28.48 | 2023 | Voquezna |
| Novo Nordisk INC | $27.50 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $14.47 | 2019 | |
| Vibrant Gastro, INC. | $13.25 | 2023 | Vibrant Starter Kit |
| Cumberland Pharmaceuticals, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.